Collegium Pharmaceutical, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Collegium Pharmaceutical, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Collegium Pharmaceutical, Inc. zu Deinem Portfolio hinzuzufügen.
STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financ...
STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the...
The prevailing market sentiment is currently fueled by the allure of "The Magnificent 7" and stocks with high upside potential. Over the last 52 weeks, the S&P 500 is up ~28% compared to the S&P Small-Cap index (~+15%). Small-cap stocks present enticing prospects for growth and value for investors willing to capitalize on calculated risks. The S&P 500 P/E is 25x vs. the S&P Small-Cap at 14.8x.
– Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled fo...
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the r...
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue's ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER,...
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.